Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Intelligent Bio Solutions's 14-Day RSI or its related term are showing as below:
INBS's 14-Day RSI is ranked better than 73.62% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 46
vs INBS: 39.54
Intelligent Bio Solutions (NAS:INBS) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Intelligent Bio Solutions 14-Day RSI Related Terms
INBS vs ITOC, WOK, BMRA: 14-Day RSI Comparison
For the Medical Devices subindustry, Intelligent Bio Solutions's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's 14-Day RSI falls into.
Intelligent Bio Solutions (NAS:INBS) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Bio Solutions (INBS) has a 14-Day RSI of 39.54 as of Jul. 20, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Intelligent Bio Solutions and its competitors. According to the industry distribution chart, Intelligent Bio Solutions ranks #229 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 26.4%.
Is Intelligent Bio Solutions' 14-Day RSI too high?
Intelligent Bio Solutions' current 14-Day RSI is 39.54. The Medical Devices & Instruments industry median 14-Day RSI is 46.00. Intelligent Bio Solutions' value of 39.54 is 14% below this industry median. Based on the distribution chart, Intelligent Bio Solutions ranks #229 out of 868 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Intelligent Bio Solutions has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' 14-Day RSI compare to ITOC and WOK?
According to the Medical Devices & Instruments industry distribution chart, Intelligent Bio Solutions ranks #229 out of 868 companies for 14-Day RSI. This puts Intelligent Bio Solutions in the upper half of its industry. The industry median 14-Day RSI is 46.00. Intelligent Bio Solutions' value of 39.54 is 14% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 46.00, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intelligent Bio Solutions's current 14-Day RSI of 39.54 is 14% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Intelligent Bio Solutions and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 46.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intelligent Bio Solutions's current 14-Day RSI is 39.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.63, compared to a current price of $2.11 — trading 19.8% below its estimated fair value. The current 14-Day RSI is 39.54 and 14% below the Medical Devices & Instruments industry median of 46.00. Intelligent Bio Solutions' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current 14-Day RSI is 39.54 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intelligent Bio Solutions (INBS) Overvalued in 2026?
Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued.
The current stock price of $2.11 is trading 19.8% below its estimated GF Value™ of $2.63.
GuruFocus considers Intelligent Bio Solutions to be Modestly Undervalued.
Key valuation signals for INBS:
14-Day RSI: 39.54
GF Value™: $2.63 vs. price of $2.11 (19.8% below fair value)
Industry Position: 14% below the Medical Devices & Instruments median (#229 of 868)
No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
48GF Score
Get the complete analysis for INBS
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBS has been successfully added to your 
